KaloBios KB004

February 2015

KaloBios Pharmaceuticals, Inc. is now recruiting the Phase 2 portion of their trial of KB004 in MF and MDS patients. The study consists of IV infusion once weekly for a 21 day dosing cycle with KB004 250 mg (the recommended Phase 2 dose). This portion of the study will be to further study the activity of KB004 and explore the safety of KB004. More detailed information is on clinicaltrials.gov

To be eligible for the study patients will have:

  • Confirmed MF or MDS with an acceptable level of EophA3 expression
  • Confirmed hematologic malignancy refractory to or progressed following standard treatments, or subjects not considered medically suitable to receive standard of care treatment or who refuse standard of care treatment
  • Acceptable level of EphA3 expression
  • Eastern Cooperative Oncology Group (ECOG) ≤1
  • Acceptable laboratory results

Patients are not eligible for the study if they have the following:

  • History of or current central nervous system (CNS) involvement that may increase risk of bleeding
  • Recent major surgery
  • Ongoing surgical or wound healing complications
  • Active clinically significant bleeding
  • Uncontrolled hypertension
  • Significant intercurrent illness
  • Known history of prolonged bleeding times or platelet dysfunction
  • Active infection requiring IV antibiotics, IV antifungals, or IV antivirals within 2 weeks prior to Cycle 1, Day 1

Study centers are now recruiting in the United States including California (Palo Alto and Sacramento), Florida (Miami and Tampa), Ohio (Cleveland), and Texas (Austin). In Australia is centers are recruiting in Westmead, New South Wales; Adelaide, South Australia; Prahran, Victoria; and Queensland, Australia. For questions, feel free to contact: add KaloBios Contact: Kate Doherty at Kdoherty@kalobios.com / 1-650-243-3126

Take the steps you need to help change your prognosis.



Get free, timely information on living with an MPN.